TNFRSF11B and breast cancer: Functioning as a decoy receptor for RANKL, lower OPG levels lead to a weaker RANKL inhibition, resulting in up to 75% higher BC risk for gBRCA1 mutation carriers with below-average OPG levels compared to high-risk patients with above-average serum levels [26].